Activity modulation of
drug metabolism
enzymes can change the biotransformation of chemotherapeutics and cellular responses induced by them. As a result,
drug-drug interactions can be modified. Acridinone derivatives, represented here by
C-1305 and
C-1311, are potent anticancer drugs. Previous studies in non-cellular systems showed that they are mechanism-based inhibitors of
cytochrome P4503A4 and undergo glucuronidation via
UDP-glucuronosyltranspherase 1A10
isoenzyme (
UGT1A10). Therefore, we investigated the potency of these compounds to modulate P4503A4 and
UGT1A10 activity in breast MCF-7 and colon HCT116
cancer cells and their influence on cytotoxicity and cellular response in cells with different expression levels of studied
isoenzymes. We show that
C-1305 and
C-1311 are inducers of not only P4503A4 but also
UGT1A10 activity. MCF-7 and HCT116 cells with high P4503A4 activity are more sensitive to acridinone derivatives and undergo apoptosis/
necrosis to a greater extent.
UGT1A10 was demonstrated to be responsible for
C-1305 and
C-1311 glucuronidation in
cancer cells and
glucuronide products were excreted outside the cell very fast. Finally, we show that glucuronidation of
C-1305 antitumor agent enhances its pro-apoptotic properties in HCT116 cells, while the cytotoxicity and cellular response induced by
C-1311 did not change after
drug glucuronidation in both cell lines.